Australian company Immutep (ASX:IMM) has reported positive results from a clinical trial of its LAG-3 immunotherapy in combination with MSD's PBS-listed anti-PD-1 therapy KEYTRUDA (pembrolizumab). …
Positive results for Australian company's cancer candidate in combination with MSD's Keytruda
May 18, 2023 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
AusBiotech and Tenmile partner to accelerate Australian life sciences
May 22, 2026 - - Latest News -
Industry chiefs want united front as agreement negotiations get underway
May 22, 2026 - - Latest News -
The sharper language will need to be accompanied by even sharper actions
May 22, 2026 - - Latest News -
Lundbeck Australia earns ninth consecutive 'Great Place to Work' certification
May 22, 2026 - - Latest News -
Merck funds Indigenous STEM leaders at Macquarie University
May 22, 2026 - - Latest News -
New report reveals how AI is now deciding which healthcare brands Australians see online
May 21, 2026 - - Latest News -
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 - - Latest News